PART I . Our Company We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimers disease (AD) and Parkinsons disease (PD). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic...
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001104659-26-027751 | EDGAR | 80K words |
| 2025-03-21 | 2024-12-31 | 0001558370-25-003482 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001558370-24-004393 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001104659-23-040275 | EDGAR | — |
| 2022-03-02 | 2021-12-31 | 0001558370-22-002668 | EDGAR | — |
| 2021-03-03 | 2020-12-31 | 0001558370-21-002303 | EDGAR | — |
| 2020-03-25 | 2019-12-31 | 0001104659-20-038326 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-110393 | EDGAR | 17K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011233 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001558370-25-007584 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0001558370-24-015074 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012227 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001558370-24-007820 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018298 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014884 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001558370-23-009142 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016902 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012561 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0001558370-22-006981 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001104659-26-034611 | EDGAR | 1K words |
| 2026-03-16 | 0001104659-26-028574 | EDGAR | — |
| 2026-02-12 | 0001104659-26-013948 | EDGAR | — |
| 2026-01-28 | 0001104659-26-007423 | EDGAR | — |
| 2025-11-13 | 0001104659-25-110548 | EDGAR | — |
| 2025-10-28 | 0001104659-25-103254 | EDGAR | — |
| 2025-10-14 | 0001104659-25-099356 | EDGAR | — |
| 2025-09-29 | 0001104659-25-094522 | EDGAR | — |
| 2025-08-15 | 0001104659-25-079248 | EDGAR | — |
| 2025-08-12 | 0001104659-25-076851 | EDGAR | — |
128 total filings indexed. 99 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001477845 |
| Ticker | ANVS |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.annovisbio.com |
| Listed | 2020-01-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report